<code id='827F1A9A48'></code><style id='827F1A9A48'></style>
    • <acronym id='827F1A9A48'></acronym>
      <center id='827F1A9A48'><center id='827F1A9A48'><tfoot id='827F1A9A48'></tfoot></center><abbr id='827F1A9A48'><dir id='827F1A9A48'><tfoot id='827F1A9A48'></tfoot><noframes id='827F1A9A48'>

    • <optgroup id='827F1A9A48'><strike id='827F1A9A48'><sup id='827F1A9A48'></sup></strike><code id='827F1A9A48'></code></optgroup>
        1. <b id='827F1A9A48'><label id='827F1A9A48'><select id='827F1A9A48'><dt id='827F1A9A48'><span id='827F1A9A48'></span></dt></select></label></b><u id='827F1A9A48'></u>
          <i id='827F1A9A48'><strike id='827F1A9A48'><tt id='827F1A9A48'><pre id='827F1A9A48'></pre></tt></strike></i>

          Home / explore / leisure time

          leisure time


          leisure time

          author:focus    Page View:357
          Franklin faces
          Adobe

          ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.

          The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.

          advertisement

          Arch declined to comment on the new fundraising.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In